沃森生物(300142.SZ)：子公司参与国家免疫规划疫苗集中采购项目入围

Core Viewpoint - Watson Bio's subsidiary, Yuxi Zerun Biotechnology Co., Ltd., has successfully entered the bid for the "2025 National Immunization Program Vaccine Centralized Procurement Project" for the bivalent human papillomavirus (HPV) vaccine, which will enhance the vaccination rate in China and support the goal of cervical cancer elimination [1][2] Group 1 - Yuxi Zerun's bivalent HPV vaccine has been included in the procurement project with a unit price of RMB 27.5 [1] - The vaccine is primarily used to prevent diseases caused by high-risk HPV types 16 and 18, including cervical cancer and related lesions [1] - The vaccine was officially launched in China in 2022 and received WHO prequalification in August 2024 [1] Group 2 - The centralized procurement is organized by the Chinese Center for Disease Control and Prevention, and Yuxi Zerun will need to sign procurement contracts and manage production and supply [2] - The inclusion in the procurement project is expected to expand the sales scale of the bivalent HPV vaccine and enhance market coverage and brand influence [2] - There are two companies included in the procurement, and negotiations with provinces for market share will take place, which may not significantly impact the company's short-term operating performance [2]